There has been no shortage of signs that Canopy Growth Corporation is steering off the course set out for it by co-founders and former co-CEOs Bruce Linton and Mark Zekulin. Perhaps the biggest has been current CEO David Klein’s admission that the company will no longer pursue the development of pharmaceutical-grade cannabis products. Speaking to […]
Canopy Growth shuns pharmaceutical research is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
Be First to Comment